Sargramostim

Generic Name
Sargramostim
Brand Names
Leukine
Drug Type
Biotech
Chemical Formula
-
CAS Number
123774-72-1
Unique Ingredient Identifier
5TAA004E22
Background

Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.

Indication

For the treatment of cancer and bone marrow transplant

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Hematopoietic Subsyndrome of Acute Radiation Syndrome, Hodgkin's Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma (NHL), Severe Infection
Associated Therapies
Allogenic bone marrow transplantation therapy, Autologous bone marrow transplantation therapy, Autologous peripheral haematopoietic stem cell transplant

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

First Posted Date
2015-01-15
Last Posted Date
2024-12-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
600
Registration Number
NCT02339571
Locations
🇺🇸

Cambridge Medical Center, Cambridge, Minnesota, United States

🇺🇸

Mercy Hospital, Coon Rapids, Minnesota, United States

🇺🇸

Essentia Health - Deer River Clinic, Deer River, Minnesota, United States

and more 737 locations

HER2-Peptide Vaccination of Patients With Solid Tumors

First Posted Date
2014-10-28
Last Posted Date
2019-11-20
Lead Sponsor
Technical University of Munich
Target Recruit Count
2
Registration Number
NCT02276300
Locations
🇩🇪

III.Medizinische Klinik und Poliklinik, Klinikum rechts der Isar der TUM, Munic, Bavaria, Germany

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

First Posted Date
2014-09-15
Last Posted Date
2016-04-19
Lead Sponsor
Benovus Bio, Inc.
Target Recruit Count
4
Registration Number
NCT02240537
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

🇺🇸

Virginia Cancer Specialists, Fairfax, Virginia, United States

Leukine (Sargramostim) for Parkinson's Disease

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-06-20
Last Posted Date
2023-10-06
Lead Sponsor
University of Nebraska
Target Recruit Count
37
Registration Number
NCT01882010
Locations
🇺🇸

Neurology Consultants of Nebraska PC, Omaha, Nebraska, United States

🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

Sargramostim for Myeloid Dendritic Cell Deficiency

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-06-06
Last Posted Date
2017-08-22
Lead Sponsor
Johns Hopkins University
Target Recruit Count
2
Registration Number
NCT01871467
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness?

First Posted Date
2012-07-31
Last Posted Date
2018-02-13
Lead Sponsor
Newcastle-upon-Tyne Hospitals NHS Trust
Target Recruit Count
64
Registration Number
NCT01653665
Locations
🇬🇧

Sunderland Royal Hospital, Sunderland, United Kingdom

🇬🇧

Freeman Hospital, Newcastle upon Tyne, Tyne And Wear, United Kingdom

🇬🇧

Queen Elizabeth Hospital, Gateshead, Tyne And Wear, United Kingdom

and more 1 locations

Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2012-01-18
Last Posted Date
2023-08-30
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
2
Registration Number
NCT01511068
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

First Posted Date
2010-07-08
Last Posted Date
2017-06-05
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
48
Registration Number
NCT01158118
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

First Posted Date
2010-06-02
Last Posted Date
2024-11-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
245
Registration Number
NCT01134614
Locations
🇺🇸

Iowa Methodist Medical Center, Des Moines, Iowa, United States

🇺🇸

Iowa-Wide Oncology Research Coalition NCORP, Des Moines, Iowa, United States

🇺🇸

Mission Cancer and Blood - Des Moines, Des Moines, Iowa, United States

and more 254 locations

Inhaled GM-CSF Therapy of Autoimmune PAP

First Posted Date
2009-05-13
Last Posted Date
2024-07-12
Lead Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Target Recruit Count
18
Registration Number
NCT00901511
Locations
🇮🇹

Fondazione IRCCS Policlinico San Matteo, Pavia, PV, Italy

© Copyright 2024. All Rights Reserved by MedPath